Valbiotis is very proud to present the Phase II/III REVERSE-IT clinical study during an oral presentation at the annual congress of the European Association for the Study of Diabetes (EASD), which takes place from 2 to 6 October 2023 in Hamburg (Germany). This presentation will detail the protocol as well as the complete characteristics of the population included, at the start of the study, during an oral session scheduled for October 3 from 12:30 p.m. to 1:30 p.m. The REVERSE-IT study, carried out in partnership with Nestlé Health Science, constitutes a world first for a non-drug active substance, both in terms of its scale (636 volunteers) and the number of centers involved internationally (52 centers in 7 countries). After a presentation in the United States last June during the prestigious congress of the American Diabetes Association, the oral communication at the EASD, the main European diabetes congress, marks the undeniable scientific success of this study on an international scale.
View the poster 